Marker Therapeutics, Inc. (MRKR) Financial Statements (2024 and earlier)

Company Profile

Business Address 4551 KENNEDY COMMERCE DR.
HOUSTON, TX 77032
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments18,1226,40111,78218,07625,82228,637
Cash and cash equivalents18,1226,40111,78218,07625,82228,637
Restricted cash and investments      182
Receivables1,7462,0832,4021,6816282
Prepaid expense2,0872,4292,4352,6662,8272,196
Total current assets:21,95610,91316,61922,42329,27631,017
Noncurrent Assets
Operating lease, right-of-use asset  5,3265,4805,6329,3049,573
Property, plant and equipment   12,323 13,74014,366
Other undisclosed noncurrent assets  11,702013,06000
Total noncurrent assets:  17,02817,80318,69123,04423,939
TOTAL ASSETS:21,95627,94134,42241,11552,32054,956
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:2,6614,5394,7055,7464,7357,349
Employee-related liabilities747
Accounts payable1,3302,8631,6122,0211,7675,016
Accrued liabilities1,3311,3472,637757796836
Other undisclosed accounts payable and accrued liabilities(0)3294562,9682,172750
Deferred revenue     182
Disposal group, including discontinued operation 260     
Due to related parties2,5005,0508,000 
Other liabilities      
Other undisclosed current liabilities  665577490738684
Total current liabilities:2,9215,2047,78211,28713,4748,215
Noncurrent Liabilities
Long-term debt and lease obligation:    7,22610,82011,036
Liabilities, other than long-term debt  6,8247,039   
Operating lease, liability  6,8247,0397,22610,82011,036
Other undisclosed noncurrent liabilities    (7,226)(10,820)(11,036)
Total noncurrent liabilities:  6,8247,0397,22610,82011,036
Total liabilities:2,92112,02814,82118,51324,29319,250
Equity
Equity, attributable to parent19,03515,91319,60122,60228,02635,706
Common stock998848483
Additional paid in capital449,527448,921447,642446,711445,216443,651
Accumulated deficit(430,501)(433,017)(428,049)(424,193)(417,273)(408,029)
Total equity:19,03515,91319,60122,60228,02635,706
TOTAL LIABILITIES AND EQUITY:21,95627,94134,42241,11552,32054,956

Income Statement (P&L) ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Revenues7634,7343,3093,950791964
Gross profit:7634,7343,3093,950791964
Operating expenses(4,897)(9,787)(7,161)(10,969)(10,070)(10,759)
Operating loss:(4,134)(5,052)(3,852)(7,019)(9,280)(9,795)
Nonoperating income
(Investment Income, Nonoperating)
3585109100363
Loss from continuing operations:(4,099)(4,968)(3,742)(6,920)(9,244)(9,792)
Loss before gain (loss) on sale of properties:(6,920)(9,244)(9,792)
Income from discontinued operations 6,615     
Other undisclosed net loss   (114)  (119)
Net income (loss) available to common stockholders, diluted:2,516(4,968)(3,856)(6,920)(9,244)(9,911)

Comprehensive Income ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Net income (loss):2,516(4,968)(3,856)(6,920)(9,244)(9,911)
Comprehensive income (loss), net of tax, attributable to parent:2,516(4,968)(3,856)(6,920)(9,244)(9,911)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: